Inclusion Criteria:  Be aged 18 to 75 years, inclusive Be willing and able to undergo a single night of actigraphy and video monitoring overnight in a laboratory Be willing and able to provide informed consent (patients only): Diagnosed with atopic dermatitis by a clinician, following the criteria listed in Table 1. (patients only): IGA score ≥ 2. (patients only): Willing and able to use only non-medicated topical therapy (i.e., bland emollient/moisturizer) for 7 days before the overnight visit. Participants should be in bed a minimum of 4 hours  Exclusion Criteria:  Any acute and/or unstable illness or medical complication which, in the opinion of a clinician, could compromise data collection and/or interpretation Use of any over-the-counter, prescription, or recreational drugs that may induce sleep or pruritus within 24 hours prior to overnight monitoring  Use of any over-the-counter or prescription treatment (systemic, or topical) that could affect the course of atopic dermatitis during the study period. Key medications are listed below:  From 3 Months prior to overnight visit: Biological products that might have significantly affected the evaluation of atopic dermatitis condition (e.g., tumor necrosis factor inhibitors, antiimmunoglobulin IgE antibodies, anti-CD20 antibodies, anti-interleukin-4 receptor) Has used systemic treatments that could affect AD within 30 days or 5 half- lives before the overnight visit. (i.e. retinoids, methotrexate, cyclosporine, hydroxycarbamide (hydroxyurea), azathioprine and systemic corticosteroids) Phototherapy treatment, laser therapy, bleach baths, tanning booths or extended sun exposure that could affect disease severity or interfere with disease assessments within 30 days before the overnight visit. Use within 21 days before the overnight visit: Topical corticosteroids that were classified as super-high potency (clobetasol propionate). Use within 14 days before the overnight visit: any other topical phosphodiesterase 4 (PDE4) inhibitor; Tacrolimus and pimecrolimus cream and/or ointment; Topical corticosteroids that were classified as low, medium, or high potency (e.g., fluocinonide, triamcinolone acetonide, desonide, hydrocortisone).  From 7 days before the overnight visit:  antibiotics antifungal or antivirus medications Antihistamines/anti-allergics: diphenhydramine, chlorpheniramine maleate, hydroxyzine) Topical phosphodiesterase 4 (PDE4) inhibitor Topical calcineurin inhibitors (tacrolimus and pimecrolimus cream and/or ointment) Topical corticosteroids that were classified as low, medium, or high potency (e.g., fluocinonide, triamcinolone acetonide, desonide, hydrocortisone) Any other topical therapy with active ingredients to treat AD or with additives that could affect AD (e.g., hyaluronic acid, urea, ceramide or filaggrin degradation products). Individuals clinically diagnosed with a sleep disorder who are NOT on a controlled treatment regime An Epworth Sleepiness Scale score of ≥11, indicating daytime hypersomnolence Previous diagnosis of a movement disorder, including but not limited to, restless legs syndrome, periodic limb movement disorder, Tourette's syndrome, tremor, or dystonia Commercial driver's license and/or high-risk occupation that could be impacted by the occurrence of daytime sleepiness Self-reported habitual sleep duration of <6 hours per night on average Shift worker, advanced/delayed circadian phase, and/or any other condition suggesting that the participant would be unable to sleep during overnight monitoring Self-reported pregnancy current or planned during the study Employee or spouse of an employee of company that designs, sells, or manufactures sleep related products and/or wearable devices (including Philips). (patients only): Any significant dermatological condition, other than atopic dermatitis, as determined by a clinician. (controls only): Any significant dermatological condition as determined by a clinician. Currently using medication for any skin disease/condition and could not, in the opinion of the investigator, tolerate restriction or discontinuation of the medication as required by the study.